International Clinical Trial: Fructose Transporter GLUT5 Mediates Histone Lactylation Modification to Regulate Hepatocellular Carcinoma Stemness and Promote Immune Evasion A Study on Its Role and Molecular Mechanism

Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500114889) titled 'Fructose Transporter GLUT5 Mediates Histone Lactylation Modification to Regulate Hepatocellular Carcinoma Stemness and Promote Immune Evasion A Study on Its Role and Molecular Mechanism' on Dec. 18, 2025.

Study Type: Observational study

Study Design: Cohort study

Primary Sponsor: Ningbo First Hospital

Condition: Hepatocellular carcinoma

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2026-01-01

Target Sample Size: Observation group:20;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=291562

Published by HT Digital Content Serv...